The LMVR is dedicated to studies of insect vectors for malaria and other infectious diseases. These investigations support research into new drug treatments, diagnostic tools, vaccines and other advancements that can lessen or even eliminate the enormous mortality and morbidity burden of vector-borne diseases. As part of this mission, the sequencing core has provided strong supports for multiple lab in LMVR for their cutting-edge genomics and genetic projects.

The NextSeq 550 System is an integrated platform that uses massively parallel sequencing technology for genetic analysis and functional genomics. We need a next-generation sequencing (NGS) system capable of sequencing a 30× human genome in a single run. Two flow cell formats and multiple reagent configurations enable data output from 20-120 Gb in a single run, providing flexibility across the broadest range of applications and study sizes. The NextSeq550 system will be applied to numerous research projects including, but not limit to, Whole-genome resequencing, ChIP-Seq, total RNA sequencing and small RNA sequencing.

Place of Performance is Rockville, MD 20852.

The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-1939011) to Skye Duffner at [email protected] by 1:00 P.M. eastern standard time, December 5, 2018. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.